此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

电子警报可改善高血压患者原发性醛固酮增多症的检测 (ALERT-PA)

2026年10月29日 更新者:Jenifer M. Brown, M.D.、Brigham and Women's Hospital

基于电子警报的计算机化决策支持可改善高血压患者原发性醛固酮增多症的检测:ALERT-PA

Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments. Despite current clinical guidelines that recommend screening in a defined set of high-risk populations, less than 5% of eligible patients are ever screened for PA. This study aims to evaluate the impact of a computer decision support Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients, referral to specialist PA care, and treatment with mineralocorticoid receptor antagonists.

研究概览

详细说明

The study protocol is a single-center Quality Improvement initiative performed as a cluster-randomized controlled trial designed to evaluate the impact of an EPIC electronic health record Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients. All patients meeting inclusion/exclusion criteria for Primary Aldosteronism (PA) screening seen over the 12-week enrollment period will comprise the study population, with randomization of alert/no alert occurring at the level of their treating clinician (Attending Physician, Nurse Practitioner, or Physician Assistant) to minimize spillover/contamination effects of the BPA onto other patients treated by the same clinician. Treating clinicians within primary care and relevant specialties including endocrinology, nephrology, and cardiology will be randomized 1:1 to receive or not receive a BPA prompting screening for PA with laboratory testing of plasma aldosterone, plasma renin activity, and a basic metabolic panel, as well as an order for an e-consult to provide guidance on interpretation of results, for eligible patients. Outcomes will be ascertained by electronic health record review at 6 months.

研究类型

介入性

注册 (实际的)

12501

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Brigham and Women's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults 18+

  • Seen by clinician at one of the intervention practices at least once in the prior 2 years

  • History of Hypertension (ICD Code) PLUS ≥1 of the below:

    • Outpatient BP >150/100 on 2 or more occasions
    • Three or more current antihypertensive medication prescriptions
    • Potassium level <3.5mEq/L or potassium supplement prescription in the last 5 years
    • History of Atrial Fibrillation or Atrial Flutter (ICD Code)

Exclusion Criteria:

  • History of Primary Aldosteronism (ICD Code)
  • Prescription for a Mineralocorticoid Receptor Antagonist (MRA) within the last 3 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:放映
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:BPA Alert Intervention

An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.

For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.

无干预:No Alert Intervention

No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Frequency of PA Testing Orders by Provider
大体时间:6 months

The primary outcome is the frequency of aldosterone/renin laboratory testing orders placed by providers.

6 months

次要结果测量

结果测量
措施说明
大体时间
Frequency of PA-related Specialty Referral
大体时间:6 months

Frequency of referral to specialist who may treat PA (endocrinology, cardiology, or nephrology)

6 months
Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription
大体时间:6 months

Frequency of prescription of empiric MRA such as spironolactone, eplerenone, or finerenone

6 months
Frequency of New PA-related Diagnoses
大体时间:6 months

Frequency of new ICD Diagnostic Code for PA, Secondary Hypertension, or Endocrine Hypertension

6 months
Frequency of E-Consult Order by Provider
大体时间:6 months

Frequency of provider ordering an E-Consult with a PA-specialist

6 months
Frequency of "Positive" PA Results
大体时间:6 months

Frequency of a suppressed plasma renin activity <=1 and aldosterone >=7.5 among patients who are screened.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jenifer M Brown, MD、Brigham and Women's Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年3月13日

初级完成 (实际的)

2024年12月9日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2023年6月22日

首先提交符合 QC 标准的

2023年6月22日

首次发布 (实际的)

2023年6月29日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2023P001435
  • 5R01HL153004-03 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅